%PDF-1.4
%
76 0 obj
<>
endobj
138 0 obj
<>/Font<>>>/Fields[]>>
endobj
74 0 obj
<>
endobj
49 1 obj
<>stream
Acrobat Distiller 5.00 for Macintosh
2004-12-07T15:36:57Z
2024-03-29T04:44:32-07:00
2024-03-29T04:44:32-07:00
QuarkXPress(tm) 5.01
application/pdf
Heather
200181.january
uuid:fe16524e-1dd1-11b2-0a00-2e0a278d5b00
uuid:fe165251-1dd1-11b2-0a00-1e0000000000
endstream
endobj
61 0 obj
<>
endobj
64 0 obj
<>
endobj
77 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
18 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
29 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
32 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
43 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
46 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
175 0 obj
[179 0 R]
endobj
176 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
0 792 612 -792 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.0369 Tc 8 0 0 8 57.2949 714.5293 Tm
(11)Tj
0.875 Tc 0.9631 0 Td
(.A)Tj
-0.00011 Tc 0.02499 Tw 1.7551 0 Td
(ydelotte MB, Kuettner KE. Heterogeneity of articular cartilage.)Tj
-0.5801 -1.25 Td
[(In: )17.7 (W)79.9 (oessner JF)79.7 (, Howell DS, editors. Joint cartilage degradation.)]TJ
0 -1.25 TD
[(New )36.8 (Y)99.8 (ork: Dekker; 1993:139-58.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Pelletier JP)110.7 (, McCollum R, Di Battista J, Loose LD, Cloutier JM,)]TJ
2.175 -1.25 Td
(Martel-Pelletier J. Regulation of normal and osteoarthritis)Tj
T*
[(chondrocyte IL-1 receptor)54.8 (. )54.8 (Arthritis Rheum 1993;1)36.8 (1:1517-27.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Dinarello CA. )17.7 (The interleukin-1 family: 10 years of discovery)64.8 (.)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(F)Tj
0.02499 Tw 0.4819 0 Td
(ASEB J 1994;8:1314-25.)Tj
-0.00011 Tc -2.6569 -1.25 Td
[(14.)-875.1 (Kayle P)110.7 (, Saal JG, Schaudt K, Zacher J, Fritz P)110.7 (, Pawelec G.)]TJ
2.175 -1.25 Td
(Determination of cytokines in synovial fluids: correlation with)Tj
T*
(diagnosis and histomorphological characteristics of synovial tissue.)Tj
0 Tc T*
(Ann Rheum Dis 1992;51:731-4.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (Chin JE, Chery )54.8 (A, Hatfield R, Krzesicki F)79.7 (, Herblin )17.7 (WF)79.7 (. Interactions)]TJ
2.175 -1.25 Td
[(between IL-1 and FGF on articular chondrocytes. Ef)17.7 (fects on cell)]TJ
T*
[(growth, prostanoid production and receptor modulation. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1991;34:314-20.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (Mehraban F)79.7 (,)-0.1 ( )17.7 (T)35 (indal MH, Prof)17.7 (fitt MM, Moskowitz R)54.8 (W)91.8 (. )17.7 (T)69.9 (emporal)]TJ
2.175 -1.25 Td
(pattern of cysteine endopeptidase \(cathepsin B\) expression in)Tj
T*
(cartilage and synovium from rabbit knees with experimental)Tj
T*
(osteoarthritis: gene expression in chondrocytes in response to)Tj
T*
[(interleukin-1 and matrix depletion. )54.8 (Ann Rheum Dis 1997;)]TJ
0 Tc 0 Tw T*
(56:108-15.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Baici )54.8 (A, Bradamante P)110.7 (. Interaction between human leukocyte)]TJ
2.175 -1.25 Td
(elastase and chondroitin sulfate. Chem Biol Interactions 1984;)Tj
0 Tw T*
[(51:1-1)36.8 (1.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (Conte )54.8 (A, Pertrini M, )17.7 (V)110.8 (aglini F)79.7 (, Polidori R. Einige biochemische)]TJ
2.175 -1.25 Td
(mechanismen der entz\237ndungshemmenden aktivit\212t von exogenem)Tj
T*
(chondroitinsulfat [Biochemical mechanisms of antiinflammatory)Tj
T*
(exogenous chondroitin sulfate]. Litera Rheumatologica 1992;)Tj
0 Tc 0 Tw T*
(14:35-42.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (Kato )36.8 (Y)128.9 (,)-0.1 ( Mukudai )36.8 (Y)128.9 (, Okimura )54.8 (A, Shimazu )54.8 (A, Nakamura S. Ef)17.7 (fects)]TJ
2.175 -1.25 Td
(of hyaluronic acid on the release of cartilage matrix proteoglycan)Tj
T*
(and fibronectin from the cell matrix layer of chondrocyte cultures:)Tj
T*
(interactions between hyaluronic acid and chondroitin sulphate)Tj
T*
(glycosaminoglycan. J Rheumatol 1995;22 Suppl 43:158-9.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Thilo G. Study of 35 cases of arthritis treated with chondroitin)]TJ
2.175 -1.25 Td
(sulphate. Schweiz Rundschau Med 1977;66:1696-9.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (Thilo G. Retrospective study of 150 cases of arthritis and 85 cases)]TJ
2.175 -1.25 Td
[(of trauma treated with chondroitin sulphate. )17.7 (Therapiewoche)]TJ
T*
(Schweiz 1987;3:869-74.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Altman R, )54.8 (Asch E, Bloch D, et al. Development of criteria for the)]TJ
2.175 -1.25 Td
(classification and reporting of osteoarthritis. Classification of)Tj
T*
[(osteoarthritis of the knee. )54.8 (Arthritis Rheum 1986;29:1039-49.)]TJ
-2.175 -1.25 Td
[(23.)-875.1 (Lequesne M, Mery C, Samson M, Gerard P)110.7 (. Indexes of severity for)]TJ
2.175 -1.25 Td
(osteoarthritis of the hip and knee. Scand J Rheumatol 1987;65)Tj
0 Tw T*
(Suppl:85-9.)Tj
0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Huskisson EC. Measurement of pain. J Rheumatol 1982;9:768-9.)]TJ
T*
[(25.)-875.1 (Kellgren JH, Lawrence JJ. Radiological assessment of)]TJ
0 Tc 2.175 -1.25 Td
[(osteoarthritis. )54.9 (Ann Rheum Dis 1957;16:494-502.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(26.)-875.1 (Dougados M, Nguyen M, Listrat )17.7 (V)128.9 (,)-0.1 ( )54.8 (Amor B. Score d\325\216quivalence)]TJ
2.175 -1.25 Td
(des anti-inflammatoires non st\216ro\225diens [Rating score of)Tj
T*
(nonsteroidal antiinflammatory agents][abstract]. Rev Rhum Mal)Tj
T*
(Osteoartic 1989;56:276.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Mazi\217res B, Loyau G, Menk\217s CJ, et al. Le chondro\225tine sulfate)]TJ
2.175 -1.25 Td
(dans le traitement de la gonarthrose et de la coxarthrose. R\216sultats \
\210)Tj
T*
(5 mois d\325une \216tude prospective multicentrique, control\216e, en do\
uble)Tj
T*
(aveugle, versus placebo [Chondroitin sulfate in treatment of knee)Tj
T*
[(and hip osteoarthritis. )54.8 (A)-220.1 (5 month prospective, multicenter)39.7 (, placebo)]TJ
T*
(controlled double blind trial]. Rev Rhum Mal Osteoartic)Tj
0 Tc 0 Tw T*
(1992;59:466-72.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875.1 (Lavori P)110.7 (.)-0.1 ( )54.8 (ANOV)128.8 (A, MANOV)128.8 (A)-220.1 (my black hen: comments on repeated)]TJ
2.175 -1.25 Td
[(measures. )54.8 (Arch Gen Psychiatry 1990;47:775-8.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (Agresti )54.8 (A. )54.8 (Analysis of ordinal categorical data. New )36.8 (Y)99.8 (ork: John)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(W)Tj
-0.00011 Tc 0.0251 Tw 0.9041 0 Td
(iley and Sons: 1982.)Tj
-3.0791 -1.25 Td
[(30.)-875.1 (Hochber)17.7 (g M, )54.8 (Altman R, Brandt K, Moskowitz R. Design and)]TJ
35.175 80 Td
(conduct of clinical trials in patients with osteoarthritis: preliminary)Tj
T*
[(recommendations from a task force osteoarthritis research society)64.8 (. )]TJ
T*
(J Rheumatol 1997;24:792-4.)Tj
-2.175 -1.225 Td
[(31.)-875.1 (Anderson JJ, Felson DT)73.9 (. Factors associated with osteoarthritis of)]TJ
2.175 -1.225 Td
(the knee in the first national Health and Nutrition Examination)Tj
0 -1.225 TD
(Survey \(HANES I\); evidence for an association with overweight,)Tj
T*
[(race, and physical demands of work. )54.8 (Am J Epidemiol)]TJ
0 Tc 0 Tw T*
(1988;128:179-89.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2 Td
[(32.)-875.1 (W)79.9 (einber)17.7 (ger M, )17.7 (T)35 (ierney )17.7 (WM, Booher P)110.7 (, Hiner SL. Social support,)]TJ
2.175 -1.2 Td
(stress and functional status in patients with osteoarthritis. Soc Sci)Tj
0 Tc 0 -1.2 TD
(Med 1990;30:503-8.)Tj
-0.00011 Tc -2.175 -1.2 Td
[(33.)-875.1 (Gillings DB, Koch G. )17.7 (The application of the principle of intention-)]TJ
2.175 -1.2 Td
(to-treat to the analysis of clinical trials. Drug Information)Tj
T*
[(Association 1991;25:41)36.8 (1-24.)]TJ
-2.175 -1.2 Td
[(34.)-875.1 (Blotman F)79.7 (, Loyau G. Clinical trial with chondroitin sulfate in)]TJ
2.175 -1.2 Td
(gonarthrosis [abstract]. Osteoarthritis Cart 1993;1:68.)Tj
-2.175 -1.2 Td
[(35.)-875.1 (Pavelka K, Manopoulo R, Bucsi L. Double-blind, dose ef)17.7 (fect study)]TJ
2.175 -1.2 Td
(of oral chondroitin 4&6 sulfate 1200 mg, 800 mg, 200 mg and)Tj
T*
(placebo in the treatment of knee osteoarthritis. Litera)Tj
T*
(Rheumatologica 1999;24:21-30.)Tj
-2.175 -1.2 Td
[(36.)-875.1 (Balblanc JC, )17.7 (V)59.8 (ignon E, Mathieu P)110.7 (, Broquet )17.7 (T)74 (, Conrozier M,)]TJ
2.175 -1.2 Td
[(Richard M. Cytokines, prostaglandines E, phospholipase )54.8 (A2 et)]TJ
T*
(m\216talloprot\216ases du liquide synovial dans l\325arthrose [Cytokines\
,)Tj
T*
[(prostaglandin E, phospholipase )54.8 (A2 and metalloproteinases in)]TJ
T*
(osteoarthritic synovial fluid]. Rev Rheum Mal Osteoartic)Tj
0 Tc 0 Tw T*
(1991;58:343-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2 Td
[(37.)-875.1 (Malaise M, Marcolongo R, Uebelhart D, )17.7 (V)59.8 (ignon E. Ef)17.7 (ficacy and)]TJ
2.175 -1.2 Td
(tolerability of 800 mg oral chondroitin 4&6 sulfate in the treatment)Tj
T*
(of knee osteoarthritis: a randomized, double-blind, multicentre)Tj
T*
(study versus placebo. Litera Rheumatologica 1999;24:31-42.)Tj
-2.175 -1.2 Td
[(38.)-875.1 (Rovati LC, Setnikar I, Forster KK, Reichelt )54.8 (A, Noak )17.7 (W)91.9 (.)]TJ
2.175 -1.2 Td
[(Glucosamine sulfate in gonarthrosis: ef)17.7 (ficacy in placebo controlled)]TJ
T*
(studies [abstract]. Rev Esp Rheum 1993;20 Suppl 1:30.)Tj
0 Tc -2.175 -1.2 Td
[(39.)-875 (Nguyen M, Dougados M, Berdah L, )54.8 (Amor B. Diacerhein in the)]TJ
-0.00011 Tc 2.175 -1.2 Td
[(treatment of osteoarthritis of the hip. )54.8 (Arthritis Rheum 1994;)]TJ
0 Tc 0 Tw T*
(37:529-36.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2 Td
[(40.)-875.1 (Caruso I, Pietrogrande )17.7 (V)128.9 (. Italian double-blind multicenter study)]TJ
2.175 -1.2 Td
(comparing S-adenosylmethionine, naproxen, and placebo in the)Tj
T*
[(treatment of degenerative joint disease. )54.8 (Am J Med 1987;83:66-71.)]TJ
-2.175 -1.2 Td
[(41.)-875.1 (Schnitzer )17.7 (TJ. Osteoarthritis treatment update: minimizing pain)]TJ
2.175 -1.2 Td
(while limiting patient risk. Postgrad Med 1993;93:89-92.)Tj
-2.175 -1.2 Td
[(42.)-875.1 (Brandt KD. Osteoarthritis. In: Fauci )54.8 (AS, Braunwald E, Isselbacher)]TJ
2.175 -1.2 Td
[(KJ, et al, editors. Harrison\325)54.8 (s principles of internal medicine. 14th)]TJ
T*
[(ed. New )36.8 (Y)99.8 (ork: McGraw-Hill; 1998:1935-41.)]TJ
-2.175 -1.2 Td
[(43.)-875.1 (V)59.8 (illani P)110.8 (,)-0.1 ( Bouvenot G. )54.8 (Approche de l\325intensit\216 de l\325ef)17.7 (fet placebo)]TJ
2.175 -1.2 Td
(dans l\325\216valuation des anti-arthrosiques symptomatiques d\325action\
)Tj
T*
[(lente [The placebo ef)17.7 (fect in assessment of long acting antiarthritic)]TJ
T*
[(drugs]. La Presse M\216dicale 1998;27:21)36.8 (1-4.)]TJ
-2.175 -1.225 Td
[(44.)-875.1 (L)91.9 (\325Hirondel JL. Klinidche doppelblind-studie mit oral verabreichtem)]TJ
2.175 -1.225 Td
(chondroitinsulfat gegen placebo bei der tibiofemoralen gonarthrose)Tj
0 -1.225 TD
(\(125 patienten\) [Double blind clinical trial of oral chondroitin)Tj
T*
(sulfate in tibiofemorial knee osteoarthritis]. Litera Rheumatologica)Tj
0 Tc 0 Tw T*
(1992;14:77-84.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(45.)-875.1 (Blotman F)79.7 (,)-0.1 ( Maheu E, )17.7 (W)39.8 (ulwik )54.8 (A, Caspard H, Lopez )54.8 (A. Ef)17.7 (ficacy and)]TJ
2.175 -1.25 Td
(safety of avocado/soybean unsaponifiables in the treatment of)Tj
0 -1.25 TD
[(symptomatic osteoarthritis of the knee and hip. )54.8 (A)-220.1 (prospective,)]TJ
T*
[(multicenter)39.7 (, three-month, randomized, double-blind, placebo-)]TJ
T*
(controlled trial. Rev Rhum Mal Osteoartic [Engl Ed] 1997;)Tj
0 Tc 0 Tw T*
(64:825-34.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(46.)-875.1 (A)73.9 (vouac B, Dropsy R. M\216thodologie des essais cliniques des)]TJ
2.175 -1.25 Td
(traitements de fond de l\325arthrose [Methodology of clinical trials for\
)Tj
T*
[(long-term treatments of osteoarthritis]. )17.7 (Th\216rapie 1993;48:315-9.)]TJ
-2.175 -1.225 Td
[(46.)-875.1 (Bellamy N, Buchanan )17.7 (WW)91.7 (, Goldsmith CH, Campbell J, Stitt L)73.9 (W)91.8 (.)]TJ
0 Tc 0 Tw 2.175 -1.225 Td
(V)Tj
-0.00011 Tc 0.02499 Tw 0.6111 0 Td
[(alidation study of )17.7 (WOMAC: a health status instrument for)]TJ
-0.6111 -1.225 Td
(measuring clinically important patient relevant outcomes to)Tj
0 -1.225 TD
(antirheumatic drug therapy in patients with osteoarthritis of the hip)Tj
T*
(or knee. J Rheumatol 1988;15:1833-40.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Mazier)36.8 (es, et al: Chondr)36.8 (oitin sulfate in OA)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(181)Tj
ET
0 0 0 0 scn
/GS0 gs
101.25 58.75 407.5 -10.833 re
f
0.5 w
/GS1 gs
101.25 58.75 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
106.328 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
84 0 obj
<>
endobj
81 0 obj
<>
endobj
117 0 obj
<>
endobj
146 0 obj
<>
endobj
80 0 obj
<>
endobj
111 0 obj
<>stream
H{PWƿ/1Cn'tT+ ZDTf)M$ᒐ.!HB !JPbUq]BnQ)v۲e/=tfkg̼s9}<
q%(h_hЧ"Bdn)WOz/=qzL\rpEA7 [ fF/I't*V&Z%puڑ,JQe)O(v%"1WKWBy8˪~x
ŗP\J*&\qJt
㧉tcMK^+S|k$3QOs|b`uav869ü1l|l`X,S06aŰD0&F`!X6Mb#x+#q1Gl6(QRl>bGدOd^ڼ)P9'Ӿ `ABW/;8/pNwwIs7z"EG]}cj Cq$(F9m9-6MC,MC^BjFV--H,qeBeQWn5Iy*5+ -Gv#-?@q~/j!
ds({|K:wR٠QK-U
R$[+U*4bEɑ@_ph-2BC⓳Rd4F9(ef9& oz'pE
j
?Ahiò3 h;WAh\ݟP؝ZycC
߃3bG$d*Ցϛ`5t9ie 1iZ
R٪K|5&)RO{613t>Эi&.)z$lMY70~QKDT$
FBsT[ix~rl!*r?2/@rTS0b~1!~M66t7N̢TaQyAMy7S_S*_k+ݥǪwK/Z^5O_DZ3/OS-*Sר
wnM0i?6rgn3!DPOXW xjCM(r.D,x /r5}&h#Rw]k2][/1+T4].C%
-m},Ni3L3T*tďtsjgnZ; g|J
{'e)-A~;#;džqui mEY?^w`5hqhok'戹=b,@p-^-N'o\u-l5G2KbC#wWFGRͳGoߤܑ]HvlmMb;ME!dǻDsքQrl~t4Ĝٿ?%_L&|LL| YZ/ujeb N.\Х?kzVQ[*SL
XȆJ+!O
A
}1Jni`w
t4ZnjWA!@+Al(
DgFS= d;S-.iY|gш8.UeU.9ԋMLɲ#%r
0m9jBˉ(0/zo=}O~C"_Eh2?GJRf>S r"T~Jh5i=_B=;MoԸ˂ή"Vw6VJ,{8ߝ
Q4dQ0$u$K0g&fJg0D+5K$$;*Pۥ͍oVn70R&Կ "z$2٦ծDArM=O+,D֣`_8yw38Ո10&bDԺq mbҫhۈ0fpGLÆ:Ec#;[!PK_مb00Lt&6lm